...
Attendees
Present | Name | Organization |
---|---|---|
xX | Nancy Cornish | CDC |
xX | Manjula Gama-Ralalage | CDC |
xX | Riki Merrick | APHL |
xX | Christina Gallegos | APHL |
xX | Amy Lui | Inductive Health / APHLx |
Raj Dash | Duke / CAP | |
xX | John Snyder | National Library of Medicine (SNOMED CT) |
xX | Andrea Pitkus | UW |
xX | Kathy Walsh | Labcorp |
x- | Rob Hausam | Hausam Consulting |
xX | Doug Franklin | APHL |
xX | Pam Banning | 3M |
Discussion topics
...
Item
...
Notes
...
Item
...
Item | Notes | ||
---|---|---|---|
Upcoming OOO |
| ||
TRUU-Lab follow up
| Dr. Sing will provide update on TRUU Lab for CLIAC April 12- update to this presentation from 2018 https://www.cdc.gov/cliac/docs/addenda/cliac0919/13_TRUU-LAB_Singh.pdf Also present to Clinical Lab Partners Forum - not scheduled yet (Heather at CDC organizing) SHIELD might put up a Test Naming topic call in May Some questions from SHIELD:
| ||
Reporting Biomarkers to Cancer registries | NOT DISCUSSED | ||
Specimen CMT - Progress |
https://app.smartsheet.com/sheets/h6JWqw5v9pwvrqWMq9r4g85CXjv9M8VvVqvHRwc1?view=grid | Specimen CMT - Hosting Options | https://app.smartsheet.com/sheets/h6JWqw5v9pwvrqWMq9r4g85CXjv9M8VvVqvHRwc1?view=grid Reviewing the discouraged terms without comments on why they are discouraged · Endometrium tissue by hysterectomy o This is listed as discouraged, but in the text for the preferred term we list this term – and the others as what folks should be using, but then we call these discouraged. o Swab is discouraged for all domains o Tissue is split between pathology and micro domain, so should be the same for both o Issue here is that we have mixed how we have used usage: § #1 for the specimen in the domain § #2 for the way we have applied the coding o We have the rule to use precoordinated code (though long term we would like type to be more clean – but that can be done based on the modeling of the pre-coordinated term, so ensure we use ONLY the specimen use in the lab domain here o Make sure we have all pre-coordinated terms for both domains o EndometriumTissueBiopsy is missing – need to add for both domains · Andrea is reviewing cancer dictionary at UW – lots of pre-coordinated terms o She will provide additional content she finds missing · Lochia o Discouraged for micro – not good to culture o Preferred specimen is vaginal discharge · Bone o Discouraged as NHSN, but preferred otherwise – we may not have reviewed the NHSN terms, so it may o Reach out to them when we are done with term review DID ANYOME ELSE TAKE MORE NOTES? |
Specimen CMT - Hosting Options |
| ||
Specimen CMT - education | NOT DISCUSSED | ||
Specimen CMT - potential pilot sites | Goal is to have some implementers lined up by April - so who to reach out to? | ||
Specimen CMT - tracking implementation impact
| NOT DISCUSSED | ||
Specimen CMT - Compare to NHS Medical Terminology testing | NOT DISCUSSED | ||
Andrea review and thoughts | Sent via email: Not very far yet (A-E terms done) in reviewing/mapping Specimen Source Site terms for cancer patients. I'm searching the Cross Map Table and a few are in there, but many are not. It might be good for me to see if I can share terms in the future so they can be added/addressed either in the cross map table or if SCT requests are needed, etc.
Some patterns I'm seeing.
I plan to investigate more on our end the information sources as they may be internal and external from our systems. If these are from clinicians, it further emphasizes a need for education/requirements/assistance for physicians as documentation/select of these terms often begins with them.
Given the impacts on pathology/cancer, PH, genetics, microbiology, and need for accurate/quality info/encoding, it might be good within SHIELD to discuss strategies (when we get our agency folks onboard)..
| ||
Specimen CMT - review of terms with questions |
| ||
10. Would ask federal agencies to review regulations/policies where specimen requirements exist (i.e. CLIA), NIH, to see if any regs need tweaking of terms/functionality to support. 11. IVD vendors with LIVD, LIDR, 510K, RWD, etc. 12. Possible other areas that may benefit: forensic testing, autopsies, 13. Education like Xavier's inquiries for micro. What's the difference between specimen type/source/procedure. How to map. Nancy mentioned CDC education. That would be good for laboratories, but what about providers, nurses, etc.? Robyn may have ideas from AMP members/testing. Is there an AMA quality area that might target their members? Medical School Education? of course the immediate pushback is physician/clinical burden. 14. Could expand to include device vendors for containers, additives too.
For CAP eCP, it would reduce pathologist burden/error potential with manual selecting in eCP. If surgeon provided and it autofilled (with allowed physician override to correct, etc.) for pathologists, radiology, etc. Wouldn't it be great if PH, cancer registry, etc. autofilled ;)
Anyhow, a few thoughts around impact in this area. Theoretically a SHIELD workgroup especially with path, micro, PH, vendors might work on the needs in each part of the process, solutions, means to adopt, policy/reg wish list, etc. | |||
Future projects for this call after CMT |
|
From Chat:
Action items
Quick decisions not requiring context or tracking
...